Who are Altace's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Renormax, Aceon, Lotensin, Monopril, Accupril, Vasotec.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ramipril.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Altace — Competitive Intelligence Brief

Altace (RAMIPRIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin Converting Enzyme Inhibitor [EPC]. Area: Metabolic.

marketed Angiotensin Converting Enzyme Inhibitor [EPC] Angiotensin-converting enzyme Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Altace (RAMIPRIL) — King Pfizer. Altace works by blocking the action of angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system that regulates blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Altace TARGET	RAMIPRIL	King Pfizer	marketed	Angiotensin Converting Enzyme Inhibitor [EPC]	Angiotensin-converting enzyme	1991-01-01
Renormax	SPIRAPRIL HYDROCHLORIDE		marketed	spirapril	Angiotensin-converting enzyme	1994-01-01
Aceon	PERINDOPRIL ARGININE	Symplmed Pharms Llc	marketed	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	1993-01-01
Lotensin	BENAZEPRIL	Validus Pharms	marketed	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	1991-01-01
Monopril	FOSINOPRIL		marketed	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	1991-01-01
Accupril	QUINAPRIL	Pfizer	marketed	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	1991-01-01
Vasotec	ENALAPRILAT	Biovail Labs Intl	marketed	enalaprilat	Angiotensin-converting enzyme	1988-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-10-05 — Aceon · 7846961 · US
2039-08-16 — Altace · 12343338 · Formulation · US

Sponsor landscape (Angiotensin Converting Enzyme Inhibitor [EPC] class)

· 1 drug in this class
King Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Altace — Competitive Intelligence Brief. https://druglandscape.com/ci/ramipril. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab